Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF)’s mission to deliver a new class of anti-infectives combatting bacterial and viral infection has been given a boost from the Australian Patent Office, which has issued notification of ‘intent to grant’ for the first of Recce’s new Patent Family 4 anti-infectives.
The patent covers the 'Process for Preparation of Biologically Active Copolymer' and expires in 2041.
The Australian Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529) and cover the process for preparation of RECCE anti-infectives, the use of R327/R529 for the treatment of disease, particularly in treatment of bacterial infections, viral infections and more.
Wide range of infections covered
In particular, the pending patent further validates RECCE® anti-infectives from studies in burn wounds, urinary tract infections, gonorrhoea, influenza, SARS-CoV-2 and several more Family 4 bacterial/viral pathogen examples.
The modes of administration covered include oral, inhalation, transdermal delivery or by injection (into the bloodstream, intramuscular and/or intravenous).
The treatment may also be applied as an aerosol, gel, topical foam or ointment, or impregnated into a dressing for application to skin or mucous membranes for transdermal or transmucosal delivery.
This is the first of Recce’s wholly-owned Family 4 patents accepted with intention to grant, with Patent Cooperation Treaty Country (PCT) patent submissions in respective stages of review.
CEO James Graham said: “With now over 40 patents around the world, validation of Recce’s new class of anti-infectives marketing/manufacturing monopolies to at least January 2041 is again welcomed as an addition to its intellectual property portfolio globally.”
Bacterial and viral pathogens covered in Family 4
Specific examples of such bacterial infections may be selected from the group of bacteria consisting of Proteus spp, Serratia spp, Pseudomonas aeruginosa, Neisseria meningitidis, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, coagulase-negative Staphylococcus spp, Streptococcus pyogenes, Streptococcus pneumoniae and Enterococcus spp.
Viral infections may be caused by coated viruses (for example, lipid-coated viruses) including herpes, HIV, cytomegalovirus and influenza.
Preferably, the viral infection treated and/or controlled by the method of the invention may be HSV-1, HSV-2, Varicella Zoster Virus (in the form of chicken pox or shingles), HCMV, EBV, Herpes 6, Herpes 7, Herpes 8 and SARS-CoV-2.
Other examples include Influenza A, Ross River virus, Coronavirus including Coronaviruses responsible for severe acute respiratory syndrome and SARS-CoV-2 – in other words, COVID-19.